Find a cancer clinical trial

    Mayo Clinic Comprehensive Cancer Center conducts hundreds of clinical trials at all phases of research. Clinical trials help us develop the future of cancer care and bring those advancements to people in need today.

    Explore our current cancer clinical trials.



    • Rochester, MN

      <p>The purpose of this study is to establish a retrospective and prospective clinical registry of patients seen in the cardio-oncology clinic to characterize trends in the composition and outcomes of the population seen in the clinic, as well as initial clinical analyses on cardiovascular toxicities.</p>

    • Jacksonville, FL

      This study is being done to determine the acceptance and effectiveness of a virtual robot assistant model at a urology clinic.

    • Scottsdale/Phoenix, AZ

      <p>The purpose of this study is to&amp;nbsp;to characterize the safety,&amp;nbsp;tolerability, and&amp;nbsp;pharmacokinetics of MRTX1719 in patients with advanced solid tumor malignancies with MTAP (methylthioadenosine phosphorylase) deletion.</p>

    • Jacksonville, FL

      <p>The purpose of this study is to assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes, and to assess the safety, tolerability, and preliminary effectiveness of the combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid leukemia.</p>

    • Scottsdale/Phoenix, AZ

      <p>The purpose of this study is to create a  long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.</p>

    • Scottsdale/Phoenix, AZ

      The purpose of this study is to test the safety and tolerability of HFB200301 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable dose of HFB200301 is determined. During the expansion part, participants will take the dose of study drug that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have.

    • Jacksonville, FL

      <p>The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including  systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models.</p> <p style="margin-left:0in; margin-right:0in"> </p>

    • Rochester, MN

      <p style="margin-left:0in; margin-right:0in">The purpose of this research is to compare two different standard-of-care pre-surgical imaging methods. </p>

    • Rochester, MN

      <p>The purpose of this study is to determine:  if the artificial intelligence (AI)-generated results are less arduous than manual tracing by radiation oncologist, and the non-inferiority of the quality of AI vs. manual tracing.  These aims will be evaluated in a clinical environment to investigate the impact of an AI algorithm on the clinical workflow. </p> <p>Radiotherapy treatment planning requires precise calculations of radiation exposure, not only for the target volumes (tissue containing malignancy), but of nearby organs-at-risk (OARs), in which the exposure needs to be minimized. Manual segmentation of these organs is a time-consuming task with high interobserver variability. Producing these segmentations automatically will reduce the time required for treatment planning and improve the interobserver variability.</p>

    • Albert Lea, MN

      <p>This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small cell lung cancer.</p>


    Fuel groundbreaking medical research!

    Your donation powers the future of medicine and helps save lives.